Oral corticosteroids in poorly controlled asthma

被引：11

作者：

Colice, GL

Stampone, P

Leung, DYM

Szefler, SJ

机构：

[1] Washington Hosp Ctr, Pulm Serv, Washington, DC 20010 USA

[2] Washington Hosp Ctr, Crit Care Serv, Washington, DC 20010 USA

[3] Washington Hosp Ctr, Resp Serv, Washington, DC 20010 USA

[4] 3M Pharmaceut, Clin Res, St Paul, MN USA

[5] Natl Jewish Med & Res Ctr, Denver, CO USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2005年 / 115卷 / 01期

关键词：

D O I：

10.1016/j.jaci.2004.07.065

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：200 / 201

页数：2

共 5 条

[1] Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma [J].

Chan, MTS ;

Leung, DYM ;

Szefler, SJ ;

Spahn, JD .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (05) :594-601

[2] Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose [J].

Davies, RJ ;

Stampone, P ;

O'Connor, BJ .

RESPIRATORY MEDICINE, 1998, 92 :23-31

[3] Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma [J].

Gross, G ;

Thompson, PJ ;

Chervinsky, P ;

Vanden Burgt, J .

CHEST, 1999, 115 (02) :343-351

[4]

*NAT ASTH ED PROGR, 1997, EXP PAN 2 REP GUID D

[5] Glucocorticoid-resistant asthma: Pathogenesis and clinical implications for management [J].

Szefler, SJ ;

Leung, DYM .

EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) :1640-1647

← 1 →